GHRP-6 and Ipamorelin are both synthetic growth hormone secretagogues that stimulate pituitary GH release through the ghrelin receptor (GHS-R1a), but they sit at opposite ends of the selectivity spectrum. GHRP-6 was one of the earliest GHRPs developed, a first-generation hexapeptide that produces potent GH release along with significant appetite stimulation, cortisol elevation, and prolactin increase. Ipamorelin, developed later, achieves GH release with remarkable selectivity — virtually no cortisol, prolactin, or appetite effects at GH-releasing doses.
This difference in selectivity is not merely academic. It determines which peptide is appropriate for a given research context, how well it is tolerated over sustained use, and whether its off-target effects are a liability or a feature. For researchers comparing these two GHS-R1a agonists, the core question is straightforward: is maximum GH potency or maximum selectivity more important for the protocol at hand?
Feature GHRP-6 Ipamorelin Structure Hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) Molecular weight ~873 Da ~711.85 Da GH release potency High Moderate Cortisol effect Measurable elevation Minimal to none Prolactin effect Mild to moderate elevation Minimal to none Appetite stimulation Strong (ghrelin-mediated) None at standard doses Tachyphylaxis Low Low Regulatory status Not approved Not approved Half-life ~15-20 minutes ~2 hours Best paired with GHRH analog for synergy GHRH analog (e.g., CJC-1295)
GHRP-6#
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a first-generation growth hormone-releasing peptide developed through systematic structure-activity studies beginning in the 1980s. It binds to GHS-R1a on pituitary somatotrophs, activating the Gq-phospholipase C-IP3 signaling cascade to trigger GH granule exocytosis.
What distinguishes GHRP-6 from more selective GHRPs is the breadth of its receptor engagement. Beyond pituitary GH release, GHRP-6 robustly activates hypothalamic ghrelin circuits involved in appetite regulation. The orexigenic (appetite-stimulating) effect is one of the most noticeable pharmacological actions of GHRP-6 — subjects typically report a pronounced increase in hunger within 20-30 minutes of administration. This effect is mediated through the same GHS-R1a receptor but in hypothalamic neurons rather than pituitary somatotrophs.
GHRP-6 also stimulates modest cortisol release through ACTH stimulation and mild prolactin elevation. These effects are dose-dependent and transient, typically returning to baseline within 1-2 hours. While less pronounced than with Hexarelin, they represent a meaningful off-target hormonal perturbation that is absent with ipamorelin.
At the hypothalamic level, GHRP-6 suppresses somatostatin release and stimulates endogenous GHRH release, creating a dual hypothalamic action that amplifies the pituitary GH signal. This effect is shared with other GHRPs and contributes to the synergistic GH release observed when GHRPs are combined with GHRH analogs.
Ipamorelin#
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide that also acts through GHS-R1a but with a binding profile that produces clean, selective GH release. In human studies, ipamorelin administered at GH-releasing doses produced dose-dependent GH secretion without significant changes in cortisol, ACTH, prolactin, FSH, LH, or TSH.
This selectivity appears to arise from ipamorelin's specific receptor-binding conformation. While GHRP-6 activates GHS-R1a broadly across multiple tissue types with varying downstream consequences, ipamorelin's interaction with the receptor appears to favor the conformational state that drives somatotroph GH release without efficiently engaging the receptor conformations responsible for appetite stimulation or ACTH release.
Ipamorelin shares the hypothalamic effects common to GHRPs — somatostatin suppression and GHRH neuron stimulation — which contribute to its utility in combination protocols. Its longer half-life (approximately 2 hours vs. 15-20 minutes for GHRP-6) provides a more sustained GH pulse, though peak GH levels are lower than with GHRP-6 at comparable doses.
GHRP-6 Side Effects#
GHRP-6's side effect profile is directly tied to its broad GHS-R1a activation:
Appetite stimulation: The most prominent and consistent effect. Intense hunger can occur within 20-30 minutes of administration and persist for 30-60 minutes. This is mediated through hypothalamic ghrelin circuits and is a pharmacological action, not a side effect per se — though it is often undesired in GH optimization contexts. Cortisol elevation: Transient, dose-dependent increase in cortisol through ACTH stimulation. Returns to baseline within 1-2 hours. Repeated cortisol elevation is a consideration for long-term protocols. Prolactin elevation: Mild and transient. Less pronounced than with GHRP-2 or Hexarelin but still measurable. Water retention: Possible at higher doses, consistent with GH-mediated fluid retention. Gastric motility: Some studies report increased gastric motility and occasional GI discomfort, related to ghrelin's well-established role in gut motility regulation. Injection site reactions: Mild and transient, common to all injectable peptides.
Ipamorelin Side Effects#
Ipamorelin is generally well-tolerated with a minimal side effect profile:
No significant cortisol or prolactin elevation: Confirmed in multiple human pharmacology studies. This is ipamorelin's defining advantage. No appetite stimulation: Unlike GHRP-6, ipamorelin does not produce noticeable hunger changes at GH-releasing doses. Mild headache: Occasionally reported in clinical studies, typically transient. Transient flushing: Mild vasodilation effects reported in some subjects. Water retention: Possible with sustained use, related to GH-mediated effects rather than the peptide itself. Injection site reactions: Mild and transient.
The tolerability difference between these peptides is significant for sustained protocols. GHRP-6's appetite stimulation can be disruptive for subjects maintaining specific dietary protocols, and repeated cortisol elevation — even if transient — is an undesirable hormonal perturbation over weeks or months of use.
GHRP-6 Dosing#
Typical research dose: 100-300 mcg per administration, subcutaneous Frequency: 2-3 times daily Timing: Best administered on an empty stomach; GH release is blunted by recent food intake. The subsequent appetite stimulation typically drives food intake within 30-60 minutes. Combination use: Most commonly paired with a GHRH analog (Sermorelin or CJC-1295 (No DAC)) administered simultaneously for synergistic GH release Saturation dose: GH response plateaus around 100-200 mcg in most studies; higher doses increase side effects without proportional GH benefit
Ipamorelin Dosing#
Typical research dose: 200-300 mcg per administration, subcutaneous Frequency: 2-3 times daily Timing: Empty stomach preferred; commonly administered before bed to augment the natural nocturnal GH pulse, and/or upon waking Combination use: Preferred GHRP partner for GHRH analog combinations; most commonly paired with CJC-1295 (No DAC) GH pulse kinetics: Onset within 15-30 minutes, peak at 30-60 minutes, return to baseline within 2-3 hours
While ipamorelin's selectivity makes it the default choice for most protocols, GHRP-6's "side effects" are contextually advantageous in specific scenarios:
Cachexia and wasting research: In subjects who are underweight or struggling with appetite, GHRP-6's potent orexigenic effect is a therapeutic feature rather than a side effect. The combination of GH release (promoting anabolism) and appetite stimulation (increasing caloric intake) addresses two aspects of wasting simultaneously.
Underweight populations: For subjects needing to increase caloric intake, GHRP-6's reliable appetite stimulation can support nutritional goals alongside GH-mediated body composition effects.
GH provocation testing: GHRP-6's higher peak GH release makes it useful as a provocation agent for evaluating pituitary GH secretory capacity. The stronger stimulus helps differentiate between partial and complete GH deficiency.
Short-term intensive protocols: For brief protocols where cumulative cortisol exposure is less of a concern, GHRP-6's higher peak GH output may justify its broader hormonal effects.
Combining GHRP-6 and ipamorelin is pharmacologically irrational, as both peptides compete for the same GHS-R1a receptor. The result would be competitive binding without synergy, likely producing a mixed response inferior to either peptide used optimally alone.
The productive combination approach is to pair one GHRP with one GHRH analog:
CJC-1295 (No DAC) + Ipamorelin: The most commonly studied clean combination Sermorelin + GHRP-6: A well-documented combination for maximum GH release where appetite stimulation is acceptable CJC-1295 DAC + Ipamorelin: Less common; combines sustained GHRH stimulation with pulsatile GHRP activation
The choice between GHRP-6 and ipamorelin is fundamentally a selectivity-potency trade-off:
Ipamorelin is the clear choice for most GH optimization research. Its selective GH release without cortisol, prolactin, or appetite effects makes it better tolerated, more practical for sustained use, and the preferred GHRP partner for combination protocols with GHRH analogs. The moderate GH release is sufficient for most research endpoints, and the clean hormonal profile avoids confounding variables in study design.
GHRP-6 is the better choice when maximum acute GH release is needed, when appetite stimulation serves the research goal, or when studying ghrelin-mediated effects beyond isolated GH release. Its extensive research history and robust dose-response data make it a well-characterized pharmacological tool.
For the majority of protocols — particularly those involving sustained dosing, combination with GHRH analogs, or body composition endpoints — ipamorelin's selectivity advantage outweighs GHRP-6's potency advantage. The chronic effects of repeated cortisol stimulation and appetite disruption are meaningful considerations that favor the cleaner peptide.
Explore the full profiles of GHRP-6 and Ipamorelin. For related comparisons, see GHRP-2 vs Ipamorelin and our comprehensive Growth Hormone Secretagogues Compared guide.
GHRP-6 Overview and Research Guide GHRP-6 Side Effects GHRP-6 Dosing Protocols Ipamorelin Overview and Research Guide Ipamorelin Side Effects Ipamorelin Dosing Protocols